NCT01647711View on ClinicalTrials.gov

A Study of Intermittent, High-dose Afatinib to Determine the Maximal Tolerated Dose and Assess Activity of This Dose Against Non-small Cell Lung Cancer With T790M Mutations

PHASE1CompletedINTERVENTIONAL
Enrollment

35

Participants

Timeline

Start Date

July 31, 2012

Primary Completion Date

September 30, 2015

Study Completion Date

September 30, 2015

Conditions
Carcinoma, Non-Small-Cell Lung
Interventions
DRUG

Dose escalation followed by treatment with MTD

Fixed 3+3 dose escalation; expansion of MTD cohort

Trial Locations (2)

Unknown

Boehringer Ingelheim Investigational Site, Aurora

Boehringer Ingelheim Investigational Site, Boston

Sponsors
All Listed Sponsors
lead

Boehringer Ingelheim

INDUSTRY